Our Story

Katrien is more than just the Managing Partner & Owner of Axes Health, she’s the driving force behind our mission. With over 25 years in the Life Sciences industry, Katrien’s passion for orphan drugs has been the driving force behind her career, since her early days at Pfizer and Genzyme. Katrien further developed her market access expertise at Bayer Healthcare and Takeda, where she gained invaluable experience in navigating complex healthcare ecosystems. Since founding Axes Health in 2019, she’s been committed to ensuring that patients, especially the vulnerable ones with rare diseases, receive the treatment they need without delay.

Most people know her as Roos, and she has a true advocate for the power of real-world data. With a PhD in Pharmacology and hands-on experience at Bayer Healthcare, she’s not just setting up early access programs—she’s redefining them. Her insights are key to navigating the complex world of pricing and reimbursement. Since 2020, she’s been a cornerstone of our team, ensuring that our strategies are as effective as they are innovative.

Science communication is more than just a skill for An-Katrien; it’s a passion. With a PhD in Ocular Drug Delivery & Nanomedicines, An-Katrien has a natural talent for simplifying complex therapeutic concepts. She’s been with us since 2022, performing in-depth analyses of several therapeutic domains and helping us to deliver strategic pricing and reimbursement advice that’s both clear and actionable. Her work ensures our strategies align with the specific needs of the local market.

Glen brings fresh energy to Axes Health, fueled by his passion for medicines thanks to his Master’s in Drug Development. He’s also diving into the exciting world of innovative payment schemes and health economics, where his enthusiasm continues to grow. While still developing his expertise in these areas, his Master’s thesis on improving patient access to CAR-T cell therapy showcases his commitment to exploring new ways to ensure patients receive timely treatment. Since joining us in 2024, Glen has been working closely with stakeholders to ensure that new therapies are not just available, but accessible in a sustainable way.